Amyotrophic Lateral Sclerosis
Conditions
Brief summary
Erythropoietin is neuroprotective in animal models of neurodegenerative diseases including amyotrophic lateral sclerosis (ALS). The aim of this study was to determine the safety and feasibility of repetitive high-dose recombinant human erythropoietin (rhEPO) therapy in ALS patients.
Interventions
DRUGrecombinant human erythropoietin(rhEPO)
Injection of erythropoietin every months (total 12 months)
Sponsors
Hanyang University Seoul Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
25 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Age between 25 to 80 * upper motor neuron signs and lower motor neuron signs were identified in neurological examination. * Meet the revised El Escorial Criteria for clinically possible, probable-laboratory -supported, probable, definite ALS. * Disease duration \< 3 years (Within 3 years from symptom onset) * ALSFRS-R score between 21 to 46 * Patient who can visit an outpatient under the aid of his or her own walking or caregivers. * The person who have agreed in writing to participate in this clinical trial by themselves and the legal representative * FVC over 50% at screening
Exclusion criteria
* Person who were not compatible with ALS * Patient with PLS or PMA * A group of patients who are concerned about the adverse effects of the drug administration (e.g. malignant hypertension,...) * ALSFRS-R score below 20 at screening * Ventilator user or Tracheostomy state patients at screening * Gastrostomy state at screening * FVC below 50% at screening or patient who cannot perform FVC test. * EKG abnormality, history of coronary stent , CABG at screening * Person who was given another clinical trial drug three months prior to screening. * History of seizure/ epilepsy * Abnormal renal function (serem creatinine \> 2.0mg/dl) * Abnormal liver function(AST/ALT/bilirubin over 2 times the upper normal limit * Pregnant * Bleeding tendency at screening * Infectious disease at screening * Drug sensitivity * Person who injected erythropoietin 6 months prior to screening * Malignant tumor * Other neurological disease (stroke, parkinson's disease, dementia...) * Psychological disease * Hb more than 16g/dL
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| changes of ALSFRS-R score | Last visit [15th visit (15 months)] | changes between score of ALSFRS-R at initial and study end point |
Countries
South Korea
Contacts
Primary ContactJinseok Park, MD
Outcome results
None listed